CII Appoints Kantipudi and Panicker to Lead CRDMO Task Force for Policy Advocacy

India's contract manufacturing policy architecture is gaining formal institutional weight: the Confederation of Indian Industry (CII) has appointed Manni Kantipudi and Manoj Kumar R. Panicker to co-lead its newly structured CRDMO task force, a move that positions organized industry advocacy at the center of India's push to compete globally in contract research, development, and manufacturing.

For multinational pharma companies sourcing active pharmaceutical ingredients or finished dosage forms from Indian CDMOs, the appointment signals a more coordinated lobbying posture from the Indian industry body. Task force structures of this kind typically shape regulatory submissions, influence GMP harmonization discussions, and feed into government consultations on manufacturing incentives, all of which carry direct consequences for supplier qualification and audit readiness at Indian contract sites.

CII's stated mandate for the task force spans policy advocacy, innovation promotion, and improving the global competitiveness of India's CRDMO sector. India's CRDMO market has expanded rapidly on the back of post-pandemic supply-chain diversification strategies among Western originators, and structured industry representation is increasingly relevant as regulators in the US, EU, and UK intensify scrutiny of foreign manufacturing sites under 21 CFR Part 211 and equivalent frameworks.

Kantipudi and Panicker bring operational and strategic profiles suited to bridging the gap between site-level manufacturing realities and national policy positioning. The task force's effectiveness will ultimately be measured against tangible outputs: draft policy recommendations, engagement with the Central Drugs Standard Control Organisation, and alignment with ICH Q10 pharmaceutical quality system principles that multinational partners routinely require of Indian contract manufacturers.

The task force's first policy submissions and engagement calendar will be the earliest measurable indicator of whether this leadership structure translates into substantive regulatory and competitive gains for India's CRDMO sector.

Source: Media4Growth via Indian Pharma Post, 3 June 2026.